| Title | Analysis of disease-dependent sedative profiles of H(1)-antihistamines by large-scale surveillance using the visual analog scale. | | Author(s) | Izumi N, Mizuguchi H, Umehara H, Ogino S, Fukui H | | Institution | Department of Molecular Pharmacology, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan. | | Source | Methods Find Exp Clin Pharmacol 2008 Apr; 30(3):225-30. | | MeSH | Adolescent
Adult
Aged
Aged, 80 and over
Asthma
Butyrophenones
Cetirizine
Child
Chlorpheniramine
Dermatitis, Atopic
Dibenzazepines
Dibenzoxepins
Female
Histamine H1 Antagonists
Histamine H1 Antagonists, Non-Sedating
Humans
Imidazoles
Japan
Male
Middle Aged
Pain Measurement
Piperidines
Population Surveillance
Psychomotor Performance
Pyridines
Quality of Life
Questionnaires
Rhinitis, Allergic, Perennial
Rhinitis, Allergic, Seasonal
Sleep Stages
Terfenadine
Urticaria
| | Abstract | Sedation is the most frequent side effect of H(1)-antihistamines, and, sometimes, it may be life-threatening for patients. Evaluation of the sedative properties of H(1)-antihistamines is important to improve the patients' quality of life (QOL). Therefore, we carried out a large-scale surveillance quantified through a questionnaire using visual analog scale (VAS) from 1,742 patients. The results showed that the degree of sleepiness caused by some nonsedative second-generation antihistamines, including fexofenadine, olopatadine and cetirizine, was disease dependent. In atopic dermatitis, an unexpectedly low VAS score of sleepiness was obtained for the first-generation antihistamine d-chlorpheniramine, which is similar to those obtained for bepotastine and epinastine. d-Chlorpheniramine also showed a high VAS score in efficacy. Meanwhile, fexofenadine showed a higher VAS score of sleepiness in atopic dermatitis than those obtained in the other allergic diseases including allergic rhinitis, urticaria and asthma. In asthma, a higher VAS score of sleepiness was found for olopatadine, ebastine and cetirizine, when compared with d-chlorpheniramine. On the other hand, bepotastine showed the lowest VAS score for sleepiness. Our findings suggest the existence of unknown factors influencing the sedative properties of H(1)-antihistamines. Therefore, appropriate H(1)-antihistamines may need to be selected, depending on allergic diseases, to improve patients' QOL. | | Language | eng | | Pub Type(s) | Journal Article
Research Support, Non-U.S. Gov't
| | PubMed ID | 18597008 |
|
